Ovid Therapeutics Inc (OVID)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $479.38M
Last updated: Nov 17, 2026 at 11:06 AM ET
Ovid Therapeutics Inc (OVID) Earnings: Report Dates and Results
Ovid Therapeutics (OVID) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, Ovid Therapeutics reported EPS of -$0.10, below the -$0.08 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
OVID has an expected report date of Mar 16, 2027.
Earnings History
Of the 39 quarters below that had an estimate, OVID beat 23 and missed 16. The widest gap in the table came in the quarter ended Dec 31, 2023, when EPS landed 340.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.10 | -$0.08 | -$0.10 - -$0.05 | -25.00% | Miss | N/A | 9 | 5 up, 0 down | Nov 10, 2026 | N/A |
| Jun 30, 2026 | -$0.08 | -$0.10 | -$0.12 - -$0.10 | +20.00% | Beat | N/A | 7 | 0 up, 4 down | Aug 13, 2026 | $733000 |
| Mar 31, 2026 | -$0.12 | -$0.11 | -$0.15 - -$0.08 | -9.09% | Miss | N/A | 5 | 1 up, 2 down | May 12, 2026 | N/A |
| Dec 31, 2025 | $0.06 | -$0.11 | -$0.11 - -$0.09 | +152.77% | Beat | N/A | 5 | 1 up, 1 down | Mar 18, 2026 | $718000 |
| Sep 30, 2025 | -$0.17 | -$0.15 | -$0.17 - -$0.13 | -13.33% | Miss | N/A | 5 | 0 up, 2 down | Nov 12, 2025 | $132000 |
| Jun 30, 2025 | -$0.06 | -$0.15 | -$0.16 - -$0.14 | +60.00% | Beat | -150.0% | 4 | 0 up, 2 down | Aug 13, 2025 | $6.27M |
| Mar 31, 2025 | -$0.14 | -$0.13 | -$0.13 - -$0.13 | -7.69% | Miss | N/A | 3 | 1 up, 0 down | May 13, 2025 | $130000 |
| Dec 31, 2024 | -$0.13 | -$0.17 | -$0.19 - -$0.15 | +22.20% | Beat | N/A | 4 | 2 up, 1 down | Mar 11, 2025 | $76000 |
| Sep 30, 2024 | -$0.20 | -$0.23 | -$0.29 - -$0.15 | +13.04% | Beat | N/A | 8 | 0 up, 0 down | Nov 12, 2024 | $173000 |
| Jun 30, 2024 | $0.12 | -$0.24 | -$0.26 - -$0.12 | +150.00% | Beat | N/A | 9 | 0 up, 0 down | Aug 13, 2024 | $169000 |
| Mar 31, 2024 | -$0.17 | -$0.23 | -$0.26 - -$0.17 | +26.09% | Beat | N/A | 8 | 0 up, 1 down | May 14, 2024 | $148000 |
| Dec 31, 2023 | -$0.22 | -$0.05 | -$0.17 - $0.25 | -340.00% | Miss | N/A | 7 | 0 up, 0 down | Mar 8, 2024 | $142000 |
| Sep 30, 2023 | -$0.16 | -$0.19 | -$0.20 - -$0.17 | +15.79% | Beat | N/A | 6 | 1 up, 0 down | Nov 3, 2023 | $109000 |
| Jun 30, 2023 | -$0.18 | -$0.21 | -$0.22 - -$0.19 | +14.29% | Beat | N/A | 5 | 0 up, 0 down | Aug 4, 2023 | $75000 |
| Mar 31, 2023 | -$0.19 | -$0.17 | -$0.18 - -$0.16 | -11.76% | Miss | N/A | 4 | 0 up, 0 down | May 5, 2023 | $66000 |
| Dec 31, 2022 | -$0.16 | -$0.18 | -$0.19 - -$0.17 | +11.11% | Beat | N/A | 4 | 0 up, 0 down | Mar 13, 2023 | $46280 |
| Sep 30, 2022 | -$0.17 | -$0.21 | -$0.23 - -$0.21 | +19.05% | Beat | N/A | 4 | 0 up, 0 down | Nov 8, 2022 | $11102 |
| Jun 30, 2022 | -$0.21 | -$0.25 | N/A | +16.00% | Beat | N/A | N/A | 0 up, 0 down | Aug 9, 2022 | N/A |
| Mar 31, 2022 | -$0.20 | -$0.21 | -$0.22 - -$0.19 | +4.76% | Beat | -107.9% | 4 | 0 up, 0 down | May 10, 2022 | $1.45M |
| Dec 31, 2021 | -$0.10 | -$0.16 | -$0.17 - -$0.15 | +37.50% | Beat | N/A | 4 | N/A | Mar 15, 2022 | N/A |
| Sep 30, 2021 | -$0.17 | -$0.18 | -$0.21 - -$0.16 | +5.56% | Beat | N/A | 5 | 0 up, 0 down | Nov 10, 2021 | N/A |
| Jun 30, 2021 | -$0.23 | -$0.16 | -$0.19 - -$0.12 | -43.75% | Miss | N/A | 5 | N/A | Aug 16, 2021 | N/A |
| Mar 31, 2021 | $2.53 | $1.13 | -$0.25 - $2.87 | +123.89% | Beat | N/A | 6 | N/A | May 13, 2021 | $208.38M |
| Dec 31, 2020 | -$0.34 | -$0.31 | -$0.41 - -$0.10 | -9.68% | Miss | N/A | 7 | N/A | Mar 15, 2021 | $5.70M |
| Sep 30, 2020 | -$0.28 | -$0.35 | -$0.45 - -$0.05 | +20.00% | Beat | N/A | 7 | N/A | Nov 12, 2020 | $6.91M |
| Jun 30, 2020 | -$0.41 | -$0.35 | -$0.38 - -$0.27 | -17.14% | Miss | N/A | 7 | N/A | Aug 10, 2020 | N/A |
| Mar 31, 2020 | -$0.37 | -$0.33 | -$0.38 - -$0.25 | -12.12% | Miss | N/A | 8 | N/A | May 7, 2020 | N/A |
| Dec 31, 2019 | -$0.35 | -$0.39 | -$0.48 - -$0.34 | +10.26% | Beat | N/A | 8 | N/A | Mar 11, 2020 | N/A |
| Sep 30, 2019 | -$0.43 | -$0.36 | -$0.40 - -$0.34 | -19.44% | Miss | N/A | 8 | N/A | Nov 8, 2019 | N/A |
| Jun 30, 2019 | -$0.34 | -$0.40 | -$0.51 - -$0.35 | +15.00% | Beat | N/A | 7 | N/A | Aug 7, 2019 | N/A |
| Mar 31, 2019 | -$0.46 | -$0.41 | -$0.54 - -$0.31 | -12.20% | Miss | N/A | 7 | N/A | May 7, 2019 | N/A |
| Dec 31, 2018 | -$0.52 | -$0.55 | -$0.62 - -$0.44 | +5.45% | Beat | N/A | 7 | N/A | Mar 7, 2019 | N/A |
| Sep 30, 2018 | -$0.53 | -$0.61 | -$0.63 - -$0.55 | +13.11% | Beat | N/A | 5 | N/A | Nov 8, 2018 | N/A |
| Jun 30, 2018 | -$0.53 | -$0.61 | -$0.68 - -$0.55 | +13.11% | Beat | N/A | 6 | N/A | Aug 9, 2018 | N/A |
| Mar 31, 2018 | -$0.54 | -$0.53 | -$0.61 - -$0.41 | -1.89% | Miss | N/A | 6 | N/A | May 8, 2018 | N/A |
| Dec 31, 2017 | -$0.45 | -$0.41 | -$0.45 - -$0.38 | -9.76% | Miss | N/A | 5 | N/A | Mar 29, 2018 | N/A |
| Sep 30, 2017 | -$0.38 | -$0.54 | N/A | +29.63% | Beat | N/A | N/A | N/A | Nov 9, 2017 | N/A |
| Jun 30, 2017 | -$0.57 | -$0.48 | N/A | -18.75% | Miss | N/A | N/A | N/A | Aug 10, 2017 | N/A |
| Mar 31, 2017 | -$3.48 | -$0.87 | N/A | -300.00% | Miss | N/A | N/A | N/A | May 5, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.31, after -$0.38 the year before. It was -$4.88 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.31 | N/A |
| Dec 31, 2024 | -$0.38 | N/A |
| Dec 31, 2023 | -$0.75 | N/A |
| Dec 31, 2022 | -$0.74 | -136.5% |
| Dec 31, 2021 | $2.03 | N/A |
| Dec 31, 2020 | -$1.40 | N/A |
| Dec 31, 2019 | -$1.58 | N/A |
| Dec 31, 2018 | -$2.12 | N/A |
| Dec 31, 2017 | -$4.88 | N/A |
Frequently Asked Questions About OVID
When is Ovid Therapeutics's next earnings date?
Ovid Therapeutics's next earnings report is expected for Mar 16, 2027.
Did OVID beat earnings estimates last quarter?
No. Ovid Therapeutics reported EPS of -$0.10 for the quarter ended Sep 30, 2026, below the -$0.08 estimate by 25.00%.
What EPS do analysts expect from OVID next quarter?
The consensus EPS estimate for Ovid Therapeutics for the quarter ending Dec 31, 2026 is -$0.10 from 14 analysts, with estimates from -$0.14 to -$0.08.
How often does OVID beat earnings estimates?
Ovid Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +24.98%.
OVID pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors